Sonelokimab (M1095)
M1095-HS-201
Phase 2 small_molecule completed
Quick answer
Sonelokimab (M1095) for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MoonLake Immunotherapeutics
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed